Strensiq (Asfotase Alfa)

Strensiq (asfotase alfa) is a prescription enzyme replacement therapy administered via subcutaneous injection. It is used to treat perinatal/infantile- and juvenile-onset hypophosphatasia, a rare metabolic bone disorder. This overview covers general uses and handling notes for informational purposes only.

Strensiq is used to address symptoms associated with hypophosphatasia, a condition characterized by impaired bone mineralization. It helps manage skeletal abnormalities and respiratory complications linked to this rare genetic disorder. Patients and caregivers often ask, 'what is Strensiq used for' in relation to bone health and mobility support. The therapy targets enzyme deficiency underlying mineralization challenges.

Users may notice improved bone strength and reduced skeletal pain over time with regular administration. Some report enhanced mobility and respiratory function as the body processes the replacement enzyme. Effects vary by individual and may take weeks or months to become apparent. Consistent use supports ongoing symptom management.

Store Strensiq refrigerated between 2°C and 8°C; do not freeze. Protect from light and keep in original packaging until use. Always check the solution for particles or discoloration before injecting. Dispose of used needles and vials in a sharps container as directed by local regulations.

Limited data exist on drug interactions with asfotase alfa. No known severe interactions with common medications like pain relievers or supplements have been reported. However, always inform your healthcare provider about all medications and supplements in use. Caution is advised when combining with other injectable therapies.